[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367243-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367243-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lung-cancerepidemiology-pathogenesis-treatment-and-molecular-aspect-review-of-literature","Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)","","Lung cancer is among the most common malignant cancers worldwide and remains the leading cause of cancer-related death. Despite continual advances in diagnosis and therapy, patient survival is still limited. Epidemiological and experimental evidence since the 1970s identifies long-term smoking as the key risk factor. This review synthesizes current data on epidemiology, pathogenesis, treatment strategies, and molecular mechanisms. It highlights actionable alterations in adenocarcinoma and ongoing research on emerging molecular targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lung-cancerepidemiology-pathogenesis-treatment-and-molecular-aspect-review-of-literature/367243/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lung-cancerepidemiology-pathogenesis-treatment-and-molecular-aspect-review-of-literature/367243.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What major risk factor is consistently linked to lung cancer development?","Question",{"text":63,"@type":64},"Long-term smoking is identified as the most important risk factor, supported by epidemiological and experimental studies since the 1970s.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How have molecular findings influenced treatment in adenocarcinoma?",{"text":68,"@type":64},"Tyrosine kinase inhibitors were developed for EGFR mutations and for ALK and ROS1 translocations, and they were approved for advanced-stage adenocarcinomas.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the status of molecular mutation evaluation in squamous cell carcinoma?",{"text":72,"@type":64},"Evaluation of these mutations is not yet used in clinical practice for squamous cell carcinoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367243,1790467352,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nLung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)  \nBeata Smolarz 1, *, Honorata Łukasiewicz 2, Dariusz Samulak 3,4, Ewa Piekarska 5, Radosław Kołaci ´nski 5 and Hanna Romanowicz 1  \nAcademic Editor: Verena Tretter  \nReceived: 27 January 2025  \nRevised: 14 February 2025  \nAccepted: 25 February 2025  \nPublished: 26 February 2025  \nCitation: Smolarz, B.; Łukasiewicz, H.; Samulak, D.; Piekarska, E.; Kołaci ´nski, R.; Romanowicz, H. Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature) . Int. J. Mol. Sci. 2025, 26, 2049. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26052049](10.3390/ijms26052049)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Laboratory of Cancer Genetics, Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, 93-338 Lodz, Poland; [hanna-romanowicz@wp.pl](hanna-romanowicz@wp.pl)  \n2 Faculty of Medicine and Health Sciences, Department of Nursing, The President Stanisław Wojciechowski Calisia University, 62-800 Kalisz, Poland; [sekretariat@szpital.kalisz.pl](sekretariat@szpital.kalisz.pl)  \n3 Department of Obstetrics and Gynecology and Gynecological Oncology, Regional Hospital in Kalisz, 62-800 Kalisz, Poland; [samulakd@wp.pl](samulakd@wp.pl)  \n4 Department of Obstetrics, The President Stanisław Wojciechowski Calisia University, 62-800 Kalisz, Poland  \n5 Regional Hospital in Kalisz, 62-800 Kalisz, Poland; [m.smol@wp.pl](m.smol@wp.pl) (E.P.); [r.kolacinski@szpital.kalisz.pl](r.kolacinski@szpital.kalisz.pl) (R.K.)  \n* Correspondence: [smolbea@wp.pl](smolbea@wp.pl); Tel.: +48-42-271-1287  \nAbstract: Lung cancer is one of the most common malignant cancers in most countries and is the leading cause of death among cancer diseases worldwide. Despite constant progress in diagnosis and therapy, survival rates of patients diagnosed with lung cancer remain unsatisfactory. Numerous epidemiological and experimental studies conducted as early asthe 1970s confirm that the most important risk factor for the development of lung cancer is long-term smoking, which remains valid to this day. In the paper, the authors present the latest data on the epidemiology, pathogenesis, treatment and molecular aspects of this cancer. In the last decade, many molecular alterations that are effective in the development of lung cancer have been discovered. In adenocarcinoma, tyrosine kinase inhibitors were developed for EGFR mutations and ALK and ROS1 translocations and were approved for use in the treatment of advanced stage adenocarcinomas. In the case of squamous cell carcinoma, the evaluation of these mutations is not yet being used in clinical practice. In addition, there are ongoing studies concerning many potential therapeutic molecular targets, such as ROS, MET, FGFR, DDR-2 and RET. Constant progress in diagnostic and therapeutic methods gives rise to hopes for an improved prognosis in patients with lung cancer.  \nKeywords: lung cancer; pathogenesis; treatment; genetics  \n1. Introduction  \nMalignant lung cancer is still a current clinical problem, posing a real threat to the entire world population [1,2] . In order to improve the statistics of early detection of lung cancer, numerous screening projects have been introduced in recent years, which at the were simultaneously intended to translate into an improvement in the prognosis of the disease [3–5] . Knowing that the risk of developing lung cancer increases in people who smoke for a long time and intensively, in the years 2002–2004 in the United States, the National Lung Screening Trial (NLST) program was implemented [6] . This study included patients from the ","cbCaieY3Ss7HwAOM","https://ap.wps.com/l/cbCaieY3Ss7HwAOM","pdf",2607002,29,"English","# Introduction\n## History of Lung Cancer","[{\"question\":\"What major risk factor is consistently linked to lung cancer development?\",\"answer\":\"Long-term smoking is identified as the most important risk factor, supported by epidemiological and experimental studies since the 1970s.\"},{\"question\":\"How have molecular findings influenced treatment in adenocarcinoma?\",\"answer\":\"Tyrosine kinase inhibitors were developed for EGFR mutations and for ALK and ROS1 translocations, and they were approved for advanced-stage adenocarcinomas.\"},{\"question\":\"What is the status of molecular mutation evaluation in squamous cell carcinoma?\",\"answer\":\"Evaluation of these mutations is not yet used in clinical practice for squamous cell carcinoma.\"}]","Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature) | PDF",1790169867,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e92d9df66f44ff444b2a2b1827d6f04.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4931e9156ca177f5ff349478f008b96.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b0056560aac206150ce28acbbece972.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa00c117be29345a74b1a5776a35566c.webp",980,1385]